HemoGenyx Pharmaceuticals Plc

As of December 31, 2025, HemoGenyx Pharmaceuticals Plc carries a market capitalization of 3.46B, placing it among publicly traded companies globally. Its enterprise value stands at 3.49B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, HemoGenyx Pharmaceuticals Plc has 6.04M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, HemoGenyx Pharmaceuticals Plc maintains a current ratio of 1.38, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, HemoGenyx Pharmaceuticals Plc's stock has declined approximately 24.79% over the past 52 weeks. The 50-day moving average sits at 571.75, while the 200-day moving average is 754.21.

As of December 31, 2025, HemoGenyx Pharmaceuticals Plc holds 158.64M in cash and equivalents against 200.42M in total debt, resulting in a net debt position of -158.64M. Total book value stands at 119.54M, with working capital of 56.49M providing operational flexibility.

HemoGenyx Pharmaceuticals Plc's most recent stock split took place on December 13, 2024 with a 400:1 split ratio.